

Manulife
Investments

Overall Morningstar Rating™:

★★★★★



Manulife Healthcare Fund[1]

Benchmark Fund of the Year Awards 2023
Outstanding Achiever in Healthcare Sector Equity
(Top Mutual Funds – Singapore)

Benchmark Fund of the Year Awards 2022
Outstanding Achiever in Healthcare Sector Equity
(Top Mutual Funds – Singapore)

[1] The full name of the fund is Manulife Global Fund – Healthcare Fund.


Overall Morningstar Rating: © Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor Manulife and its affiliates are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results. The rating shown is for Class AA, as of Mar 2026.

Benchmark Fund of the Year Awards 2023, 2022: For more information, please visit benchmark.today/fund-awards-2023/ and benchmark.today/fund-awards-2022/.

1 Attractive long-term opportunity


Healthcare outperformed the broad equity market and most other sectors over the long term.

Total returns (31 Dec 1994 – 31 Mar 2026)[2]



2 Resilience during economic downturns

Healthcare also demonstrated resilience during economic downturns[3], due to the inelastic nature of demand for healthcare products and services.



3 Long-term secular trends

The global population is aging and there will be more demand for healthcare products and services, as well as increased investments in attaining medical breakthroughs.

Ageing population[4]

Nearly **22%** of the global population will be **60 years old and above by 2050**

Rising healthcare spend[5]

The US spent **17%** of its gross domestic product on healthcare in 2022, an **increase of more than twofold over the last 20 years**

Investments in medical advances[6]

The US Food & Drug Administration has approved more than **400** novel drugs from 2015 to date, **an average of 45 approvals a year**

[2] Source: Bloomberg, as of 31 Mar 2026. Rebased at 100 as of Dec 1994. Past performance is not indicative of future results. It is not possible to directly invest in an index. [3] Source: Morningstar, as of 31 Mar 2026. Past performance is not indicative of future results. [4] https://www.who.int/news-room/fact-sheets/detail/ageing-and-health [5] https://data.oecd.org/healthres/health-spending.htm [6] https://www.fda.gov/drugs/development-approval-process-drugs/drug-approvals-and-databases

Why Manulife Healthcare Fund

Three *guiding principles*

The investment team is guided by these 3 principles in implementing the strategy and believes that healthcare companies with products and services that address these principles should potentially see unprecedented demand.

Stock selection in action[7]

Unmet medical needs

US-based biopharmaceutical giant that seeks to address major global health challenges, such as diabetes, obesity, Alzheimer's, and immune system disorders

Underappreciated opportunities


UK-based industry leader that conducts R&D of prescription medicines in oncology, rare diseases, and biopharmaceuticals

Ability to bend cost curve

A diversified med-tech company that generated incremental cash flows from ventilator sales during the Covid-19 pandemic, some of which were re-deployed in funding clinical trials for a catheter-based approach for treatment of resistant hypertension

Consistent track record

Cumulative growth of US$100 since inception (as of 31 Mar 2026)[8]



Experienced team with a collaborative culture[9]



Steve Slaughter
Lead Portfolio Manager
Global healthcare
39 years of experience



C.J. Sylvester
Portfolio Manager
Global therapeutics
28 years of experience

[7] For informational purposes only and not intended to constitute a recommendation to buy or sell any security or to adopt any investment strategy. [8] Cumulative return is 234.9% on offer-to-bid basis. Since inception (27 June 2008), the class returned 7.35% (annualised) on NAV-to-NAV basis and 7.04% (annualised) on offer-to-bid basis. Performance figures are calculated with all dividends and distributions reinvested, taking into account all charges which would have been payable upon such reinvestment. Past performance is not indicative of future results. [9] As of 31 Mar 2026. Steve Slaughter will be retiring from the organization, effective 31 Dec 2026. C.J. Sylvester was named co-lead portfolio manager, effective 29 Jan 2026, and will be named lead portfolio manager, effective 31 Dec 2026.


Fund details

Investment objective	The Fund aims to provide medium to long-term capital growth for those who hold a long-term investment view and who are prepared to accept significant fluctuations in the value of their investments in order to achieve long-term returns.
Inception date	27 Jun 2008
ISIN code	LU0357321016
Bloomberg ticker	MGFHEAL LX
Base currency	USD
Minimum investment	USD 1,000 (or equivalent in major currencies)
Management fee	1.5% of NAV per annum
Initial sales charge	Up to 5%
Dealing frequency	Daily
Investment manager	Manulife Investment Management (US) LLC
Fund size	USD 385.2 million

Download the fund factsheet

Top holdings[10]	%
Eli Lilly and Company	9.67
AstraZeneca plc	6.21
Johnson & Johnson	6.11
AbbVie Inc	5.75
Medtronic plc	4.85
McKesson Corp	4.54
Stryker Corp	4.32
Amgen Inc	4.30
Abbott Laboratories	3.54
Thermo Fisher Scientific Inc	3.21

Sector allocation (%)[10]



[10] Source: Manulife Investment Management, as of 28 Feb 2026. Allocations are subject to change at any time.

Important information

Manulife Global Fund (the "Company") is an open-ended investment company registered in the Grand Duchy of Luxembourg. The Manulife Global Fund – Healthcare Fund ("the Fund") is recognised under the Securities and Futures Act of Singapore for retail distribution. The Company has appointed Manulife Investment Management (Singapore) Pte. Ltd. as its Singapore Representative and agent for service of process in Singapore. The information provided herein does not constitute financial advice, an offer or recommendation with respect to the Fund. Opinions, forecasts and estimates on the economy, financial markets or economic trends of the markets mentioned herein are not necessarily indicative of the future or likely performance of the Fund. **The Fund may use financial derivative instruments for the purposes of investment, efficient portfolio management and/or hedging. Investors should note that the Fund may have a high volatility to its net asset value as a result of its investment policy or portfolio management techniques.** Investments in the Fund are not deposits in, guaranteed or insured by the Manager and involve risks. Past performance of the manager or sub-manager is not necessarily indicative of its future performance. The value of units in the Fund and any income accruing to them may fall or rise. Past performance of the Fund is not necessarily indicative of future performance. Investors should read the Singapore prospectus and seek advice from a financial adviser before deciding whether to purchase units in the Fund. A copy of the Singapore prospectus and the product highlights sheet can be obtained from Manulife or its distributors. In the event an investor chooses not to seek advice from a financial adviser, he should consider whether the Fund is suitable for him. **Distributions are not guaranteed.** Investors should refer to the Singapore prospectus for the distribution policy of the Fund. The Directors of the Company shall have the absolute discretion to determine whether a distribution is to be made in respect of the Fund as well as the rate and frequency of distributions to be made. Distributions may be made out of (a) income, or (b) net realized gains, or (c) capital of the Fund, or (d) gross income while charging all or part of the fees and expenses to capital, or (e) any combination of (a), (b), (c) and/or (d). Past distribution yields and payments are not necessarily indicative of future distribution yields and payments. Any payment of distributions by the Fund is expected to result in an immediate decrease in the net asset value per share of the Fund.

This advertisement or publication has not been reviewed by the Monetary Authority of Singapore.

Information is as of 31 Mar 2026, unless otherwise stated. 3194004